Pfizer taps Dewpoint Therapeutics in $239M dystrophy drug deal

Authors Ben Adams
Published January 6, 2021
Source View at FierceBiotech

Fierce 15 winner Dewpoint Therapeutics has added Pfizer to its growing list of pharma partners looking to tap the startup’s next-gen approach to a host of diseases.

The U.S.-German biotech is working on condensates, a new area of research that is helping explain aspects of cell biology that have been mysterious to researchers…

Join the conversation

Create an Account or Sign In to comment.